Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 17/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 17/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6133299 | 0.99 | ADORA2A (0.46) | ADORA2AADORA1NOS1ADORA3ADORA2B | |
| SCHEMBL6134444 | 0.91 | ADORA2A (0.51) | ADORA2AADORA1HRH3 | |
| SCHEMBL6133573 | 0.90 | ADORA2A (0.50) | ADORA2AADORA1NOS1ADORA3ADORA2B | |
| SCHEMBL6133520 | 0.90 | HRH4 (0.43) | ADORA2AADORA1HRH3ALDH1A1 | |
| SCHEMBL6134544 | 0.82 | ADORA2A (0.46) | ADORA2AADORA1 | |
| SCHEMBL5149031 | 0.82 | ALDH1A1 (0.41) | ADORA2AADORA1NOS1HRH3ALDH1A1 | |
| SCHEMBL6133734 | 0.82 | ADORA2A (0.45) | ADORA2AADORA1ADORA2B | |
| SCHEMBL6134523 | 0.82 | ADORA2A (0.45) | ADORA2AADORA1ADORA2B | |
| SCHEMBL6134022 | 0.82 | ADORA2A (0.45) | ADORA2AADORA1 | |
| SCHEMBL5152699 | 0.81 | MAPT (0.40) | ADORA2AADORA1NOS1HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ASTELLAS PHARMA INC. (JP) | 2005-02-24 | — | — | US | disclosed |
| WO-2003057689-A1 | AMINOPYRIMIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ADORA2B, ADORA2A, ADORA1 | ADORA2A 2/4885ADORA1 3/4885NOS1 2284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.